Drug Trial Radar · NCT00005044
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,579
Actual
Start
Feb 2000
Primary completion
Sep 2012
Study completion May 20, 2022
Sponsor
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.
Conditions
- Prostate Cancer
Interventions
CasodexDrug
Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
EulexinDrug
Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
LHRH agonistDrug
LHRH agonist of choice. The manufacturer's instructions should be followed.
radiation therapyRadiation
\[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-specific Survival (DSS) (10-year Rates Reported)Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
Locations
261 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama
Comprehensive Cancer Institute
Huntsville, Alabama
Huntsville Hospital
Huntsville, Alabama
MBCCOP - Gulf Coast
Mobile, Alabama
Montgomery Cancer Center
Montgomery, Alabama
DCH Cancer Treatment Center
Tuscaloosa, Alabama
Foundation for Cancer Research and Education
Phoenix, Arizona
Providence Saint Joseph Medical Center - Burbank
Burbank, California
Mount Diablo Medical Center
Concord, California
City of Hope Comprehensive Cancer Center
Duarte, California
California Cancer Center
Fresno, California
Saint Agnes Cancer Center
Fresno, California
Sutter Health Western Division Cancer Research Group
Greenbrae, California
Loma Linda University Cancer Institute at Loma Linda University Medical Center
Loma Linda, California
Veterans Affairs Medical Center - Long Beach
Long Beach, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
CCOP - Bay Area Tumor Institute
Oakland, California
Huntington Cancer Center at Huntington Hospital
Pasadena, California
Robert and Beverly Lewis Family Cancer Care Center
Pomona, California
Radiation Oncology Center - Sacramento
Sacramento, California
Radiation Medical Group, Incorporated
San Diego, California
Naval Medical Center - San Diego
San Diego, California
UCSF Comprehensive Cancer Center
San Francisco, California
O'Connor Hospital
San Jose, California
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California
Torrance Memorial Medical Center
Torrance, California
David Grant Medical Center
Travis Air Force Base, California
Memorial Hospital Cancer Center
Colorado Springs, Colorado
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Denver, Colorado
CCOP - Colorado Cancer Research Program, Incorporated
Denver, Colorado
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado
Hospital of St. Raphael
New Haven, Connecticut
Yale Comprehensive Cancer Center
New Haven, Connecticut
CCOP - Christiana Care Health Services
Newark, Delaware
Sibley Memorial Hospital
Washington D.C., District of Columbia
21st Century Oncology - Fort Myers
Fort Myers, Florida
Shands Cancer Center at the University of Florida Health Science Center
Gainesville, Florida
Florida Radiation Oncology Group
Jacksonville, Florida
Holmes Regional Medical Center
Melbourne, Florida
Showing 40 of 261 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.